Clinical Trial Details

Trial ID: L0373
Source ID: NCT05147090
Associated Drug: Empagliflozin
Title: Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With Significant/Advanced Fibrosis or Cirrhosis: a Randomized, Double-blind Placebo-controlled Trial
Acronym: --
Status: Not recruiting
Study Results: No Results Available
Results: --
Conditions: Chronic Hepatitis b;NAFLD;Cirrhosis;Fibrosis, Liver;Empagliflozin;SGLT2 Inhibitors
Interventions: Drug: Empagliflozin 10 MG;Drug: Placebo pills
Outcome Measures: Change in liver stiffness (measured by MRE)Remission of significant/advanced fibrosis and cirrhosis;Progression of significant/advanced fibrosis to cirrhosis (measured by MRE);Progression to decompensated cirrhosis;Change in liver stiffness (measured by transient elastography);Change in fat content (measured by transient elastography);Changes of alanine aminotransferase (ALT);Changes of aspartate aminotransferase (AST);Changes of alkaline phosphatase (ALP);Changes of gamma glutamyl transferase (GGT);Changes of fasting glucose;Changes of haemoglobin A1c (HbA1c);Changes of total cholesterol;Changes of low density lipoprotein (LDL);Changes of high density lipoprotein (HDL);Changes of body weight;Changes of body mass index (BMI);Changes of waist circumference;Changes of systolic blood pressure;Changes of diastolic blood pressure
Sponsor/Collaborators: The University of Hong Kong
Gender: All
Age: 18 Years80 Years
Phases: Phase 4
Enrollment: 106
Study Type: Interventional
Study Designs: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Start Date: 22/11/2021
Completion Date: --
Results First Posted: --
Last Update Posted: 21 December 2021
Locations: --
URL: https://clinicaltrials.gov/show/NCT05147090